Becton Dickinson & Co.
BDX
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2026
May 7, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
322.4% upsideUndervalued by 322.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $53.30 Billion |
|---|---|
| Enterprise Value | $69.77 Billion |
| Dividend Yield | $3.51 (2.39%) |
| Earnings per Share | $5.84 |
| Beta | 0.29 |
| Outstanding Shares | 280,640,000 |
Return
| Return on Equity | 4.62% |
|---|---|
| Return on Assets | 2.20% |
| Return on Invested Capital | 5.51% |
Valuation & Multiples
| P/E Ratio | 36.28 |
|---|---|
| PEG | -18.05 |
| Price to Sales | 1.92 |
| Price to Book Ratio | 1.71 |
| Enterprise Value to Revenue | 3.27 |
| Enterprise Value to EBIT | 29.93 |
| Enterprise Value to Net Income | 62 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.72 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5368▲ 9.34% |
|---|---|
| Total Calls | 613,501▼ 71.96% |
| Total Puts | 329,344▼ 66.06% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 92.01%▼ 15.01% |
|---|---|
| Total Invested | $42.01B▼ 54.51% |
| Investors Holding | 1,483▼ 96.00% |
ESG Score
No data
About Becton, Dickinson And Co.
72,000 employees
CEO: Thomas Polen BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of hea...
Relevant Senate Committees
This committee's expertise and official 'revenue estimates' directly influence the development and analysis of corporate tax structures and policies, which have a profound impact on BD's profitability and investment strategies.
As the committee controlling taxation, international trade, and entitlement spending (like Medicare and Medicaid), it directly impacts BD's corporate tax burden, global trade operations, and the critical reimbursement landscape for its medical products in the US.
This committee directly allocates federal spending across various sectors, including healthcare, defense, and scientific research, profoundly influencing funding available for medical device procurement by customers and related research important to BD.
This committee directly regulates the FDA, which is critical for the approval, marketing, and oversight of BD's medical devices and diagnostics, and influences NIH funding for research that could impact future product development.
The committee's oversight of antitrust laws and intellectual property rights is highly relevant to BD, influencing potential mergers and acquisitions, protecting its patented medical technologies, and ensuring fair market competition.
This committee's funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and medical device manufacturers, making it a direct influence on a significant customer segment for BD (e.g., VA hospitals).